Industry News

• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc. March 11, 2010  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc. March 11, 2010  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott March 11, 2010  
• Cordis unveils next generation CoCr coronary stent  Cordis Corporation announced the European launch of its next generation of bare metal stent system - PRESILLION(TM) PLUS. The new stent system, which improves upon the ground-breaking PRESILLION(TM), features important technological advances.
  Johnson & Johnson March 11, 2010  
• Dr. Francis S. Collins receives Albany Medical Center Prize  NIH Director Francis S. Collins, M.D., Ph.D. has been named a recipient of the Albany Medical Center Prize in Medicine and Biomedical Research for his leading role in mapping the human genome.
  National Institutes of Health March 10, 2010  
• Monsanto ranks no. 28 on the 2010 DiversityInc Top 50 Companies for Diversity(R) list  Monsanto Company has been named to The 2010 DiversityInc Top 50 Companies for Diversity(R) list for its demonstrated use of measurable diversity best practices and results. A total of 449 companies participated this year, up 12 percent from last year.
  Monsanto Company March 10, 2010  
• Abbott receives U.S. FDA approval for new cataract multifocal intraocular lens  Abbott announced it has received U.S. Food and Drug Administration (FDA) approval for the TECNIS(R) Multifocal 1-Piece intraocular lens (IOL) for cataract patients with and without presbyopia.
  Abbott March 10, 2010  
• FDA approves Botox to treat spasticity in flexor muscles of the elbow, wrist and fingers  The U.S. Food and Drug Administration approved Botox (onabotulinumtoxin A) to treat spasticity in the flexor muscles of the elbow, wrist, and fingers in adults. Spasticity is common after stroke, traumatic brain injury, or the progression of multiple sclerosis.
  FDA March 09, 2010  
• Abbott enhances pharmaceutical pipeline with acquisition of Facet Biotech  Abbott and Facet Biotech announced a definitive agreement for Abbott to acquire Facet, enhancing Abbott's early- and mid-stage pharmaceutical pipeline.
  Abbott March 09, 2010  
• Vaccinating children against flu helps protect wider community  Results of a clinical trial conducted in a largely self-contained religious community during the 2008-09 influenza season show that immunizing children against seasonal influenza can significantly protect unvaccinated community members against influenza as well.
  National Institutes of Health March 09, 2010  

   (next 10 articles)